In 47 states (plus the District of Columbia), non-physician-owned corporations cannot practice medicine. This is the Corporate Practice of Medicine (CPOM) doctrine — one of the oldest principles in healthcare law — and it exists to prevent corporate profit motives from overriding clinical judgment.
Every venture-backed GLP-1 telehealth startup technically violates the spirit of this doctrine while staying within its legal letter. Here's how.
The two-entity structure
A typical GLP-1 telehealth company is actually two (or more) legal entities:
Entity 1: The Management Services Organization (MSO). This is the company you interact with. It builds the website, runs the ads, processes your payment, handles customer support, manages the technology platform, and coordinates the pharmacy relationship. It is typically a C-corp or LLC, owned by non-physicians, funded by venture capital or private equity. It is not a medical practice and cannot prescribe medications.
Entity 2: The Professional Corporation (PC) or Professional LLC (PLLC). This is a clinician-owned entity — typically owned by a single physician (the "medical director") — that holds the medical license allowing the practice of medicine. The NPs and PAs who review your intake and sign your prescription are employed by or contracted through this entity. All clinical decisions are made within this entity.
The MSO provides "management services" to the PC under a services agreement. The MSO handles everything except the clinical decisions. The PC handles the clinical decisions and nothing else. On paper, the physician-owner of the PC controls the clinical practice independently. In practice, the MSO controls essentially everything that determines the patient experience.
Why this structure matters to you
Accountability is split
When something goes wrong — a prescribing error, a missed contraindication, a side effect that wasn't followed up on — the accountability chain is fractured. The MSO that designed the intake flow, set the volume expectations, chose the pharmacy, and processed your payment bears no direct clinical liability. The PC and its clinicians bear the clinical liability, even though they operate within a system the MSO controls.
This means the entity with the money and the power (the MSO) has limited liability, while the entity with the liability (the PC) has limited power to change the system. The incentive alignment problem is built into the structure.
The "medical director" may be nominal
The physician who owns the PC and serves as medical director may be deeply involved in clinical protocol development, quality assurance, and adverse event review. Or they may be a name on a filing whose primary function is to satisfy the CPOM doctrine's requirement for physician ownership. The range is vast, and from the outside, you can't easily tell which end of the spectrum your platform's medical director occupies.
Clinician independence is structural, not guaranteed
CPOM doctrine is designed to ensure that clinical decisions are made by clinicians, not by corporations. But when the MSO controls the intake funnel (which patients the clinician sees), the technology platform (how much time and information the clinician has to review each case), the compensation structure (whether clinicians are paid per review, incentivizing volume), and the pharmacy relationship (which drugs are available to prescribe), the clinician's "independent" judgment operates within constraints that the MSO defined.
A clinician who consistently rejects patients the MSO sent through its funnel — or who insists on longer review times that reduce throughput — may find their contract not renewed. This pressure doesn't require explicit direction. The structure creates it.
The three exceptions
Three states — California, Texas, and New York — have the strongest CPOM enforcement and have produced case law that tests the boundaries of the MSO model in telehealth. Platforms operating in these states face higher scrutiny on the question of whether the MSO is improperly directing clinical decisions.
California's Medical Board, in particular, has signaled interest in examining whether MSO service agreements in telehealth effectively constitute the corporate practice of medicine — even when the formal structure separates the entities. If California brings an enforcement action against a GLP-1 MSO, the implications would ripple across the industry.
How to evaluate the structure from the outside
You can't audit a company's MSO agreement from your couch. But you can look for signals:
Does the platform name its medical practice entity? Some platforms (particularly those built by physicians) prominently identify the PC/PLLC that provides clinical services. This transparency is a positive signal.
Does the medical director appear to have real authority? A medical director who publishes clinical protocols, appears in educational content, and maintains an active professional presence outside the platform is more likely to exercise genuine oversight than a name in a filing.
Does the clinical experience feel like medicine or like shopping? If your entire GLP-1 experience — from first click to autoship — feels indistinguishable from ordering supplements on Amazon, the MSO has likely optimized the patient journey for conversion, not clinical care. Medicine should feel at least a little like medicine.
What should change
The MSO model isn't inherently bad. Some of the best-run healthcare companies in the country use it. The model becomes problematic when the services agreement gives the MSO de facto control over clinical decision-making — when "management services" effectively includes "deciding how many patients a clinician reviews per hour" or "determining which intake form responses trigger automatic approval."
The reform most likely to produce real change: requiring GLP-1 telehealth platforms to register with state medical boards as telehealth entities, not just through individual clinician licenses. This would give medical boards the ability to audit the MSO's clinical protocols — not just the clinician's individual performance — and to hold the entity accountable when systemic issues produce systemic failures.
Until then, the MSO structure is the water you're swimming in. Knowing it's there doesn't change its temperature, but it helps you understand the currents.